Advertisement
Journal of Clinical Oncology  
Search for:
Limit by:
  Browse by Subject or Issue
Home Search or Browse JCO My JCO Subscriptions Customer Service Site Map

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a colleague
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Save to my personal folders
Right arrow Download to citation manager
Right arrowRights & Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Stiggelbout, A. M.
Right arrow Articles by de Haes, J. C.J.M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Stiggelbout, A. M.
Right arrow Articles by de Haes, J. C.J.M.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Facebook   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?
Journal of Clinical Oncology, Vol 19, Issue 1 (January), 2001: 220-230
© 2001 American Society for Clinical Oncology

Patient Preference for Cancer Therapy: An Overview of Measurement Approaches

By A. M. Stiggelbout, J. C.J.M. de Haes

From the Department of Medical Decision Making, Leiden University Medical Center, Leiden, and Department of Medical Psychology, Academic Medical Center, University of Amsterdam, Amsterdam, the Netherlands.

Address reprint to A.M. Stiggelbout, PhD, Medical Decision Making Unit, Leiden University Medical Center, PO Box 9600, 2300 RC Leiden, the Netherlands; email Stiggelbout{at}rullf2.medfac.leidenuniv.nl

PURPOSE: In the era of evidence-based medicine and shared decision making, the formal assessment of patient preference for treatments or treatment outcomes has attracted much attention. In this article, the two most common approaches to the evaluation of preference, ie, utility assessment and probability trade-off assessment, are described. The purpose is to provide clinicians with the background knowledge needed to interpret preference studies published in the literature and to judge whether the reported findings are relevant to their own patients.

METHODS: An overview is given of the methods used to assess utilities and probability trade-off scores. Evidence on determinants of such scores is presented. Examples from oncology are provided. Because experience with the treatment plays an important role as a determinant of preferences for both treatments and treatment outcomes, special attention is paid to the interpretation of studies in the light of subject selection. Directions for future research are suggested.

CONCLUSION: The choice of approach and the measuring instrument depend on the goal of the preference assessment. Normal psychologic processes, such as coping, adaptation, and cognitive dissonance reduction, cause patients who are about to undergo a therapy or have experienced a therapy to rate it more favorably than other patients do. This should be remembered when using evidence from the literature to inform patients or for patient decision making.


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Facebook Facebook   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?


This article has been cited by other articles:


Home page
Med Decis MakingHome page
T. Salz and N. T. Brewer
Offering Chemotherapy and Hospice Jointly: One Solution to Hospice Underuse
Med Decis Making, July 1, 2009; 29(4): 521 - 531.
[Abstract] [PDF]


Home page
Med Decis MakingHome page
E. R. Bossema, C. A. M. Marijnen, M. C. M. Baas-Thijssen, C. J. H. van de Velde, and A. M. Stiggelbout
Evaluation of the Treatment Tradeoff Method in Rectal Cancer Patients: Is Surgery Preference Related to Outcome Utilities?
Med Decis Making, November 1, 2008; 28(6): 888 - 898.
[Abstract] [PDF]


Home page
CA Cancer J ClinHome page
Y.-C. T. Shih and M. T. Halpern
Economic Evaluations of Medical Care Interventions for Cancer Patients: How, Why, and What Does it Mean?
CA Cancer J Clin, July 1, 2008; 58(4): 231 - 244.
[Abstract] [Full Text] [PDF]


Home page
Med Decis MakingHome page
D. J. McLernon, J. Dillon, and P. T. Donnan
Systematic Review: Health-State Utilities in Liver Disease: A Systematic Review
Med Decis Making, July 1, 2008; 28(4): 582 - 592.
[Abstract] [PDF]


Home page
Arch SurgHome page
J. D. Harrison, M. J. Solomon, J. M. Young, A. Meagher, P. Butow, G. Salkeld, G. Hruby, and S. Clarke
Patient and Physician Preferences for Surgical and Adjuvant Treatment Options for Rectal Cancer
Arch Surg, April 1, 2008; 143(4): 389 - 394.
[Abstract] [Full Text] [PDF]


Home page
Anesth. Analg.Home page
T. R. Vetter
A Primer on Health-Related Quality of Life in Chronic Pain Medicine
Anesth. Analg., March 1, 2007; 104(3): 703 - 718.
[Abstract] [Full Text] [PDF]


Home page
Med Decis MakingHome page
E. B. Elkin, M. E. Cowen, D. Cahill, M. Steffel, and M. W. Kattan
Preference Assessment Method Affects Decision-Analytic Recommendations: A Prostate Cancer Treatment Example
Med Decis Making, October 1, 2004; 24(5): 504 - 510.
[Abstract] [PDF]


Home page
JCOHome page
H. de Haes, M. Olschewski, M. Kaufmann, M. Schumacher, W. Jonat, and W. Sauerbrei
Quality of Life in Goserelin-Treated Versus Cyclophosphamide + Methotrexate + Fluorouracil-Treated Premenopausal and Perimenopausal Patients With Node-Positive, Early Breast Cancer: The Zoladex Early Breast Cancer Research Association Trialists Group
J. Clin. Oncol., December 15, 2003; 21(24): 4510 - 4516.
[Abstract] [Full Text] [PDF]


Home page
The OncologistHome page
C. T. Chung and R. W. Carlson
Goals and Objectives in the Management of Metastatic Breast Cancer
Oncologist, December 1, 2003; 8(6): 514 - 520.
[Abstract] [Full Text] [PDF]


Home page
Ann OncolHome page
F. Cardoso, A. Di Leo, C. Lohrisch, C. Bernard, F. Ferreira, and M. J. Piccart
Second and subsequent lines of chemotherapy for metastatic breast cancer: what did we learn in the last two decades?
Ann. Onc., February 20, 2002; 13(2): 197 - 207.
[Abstract] [Full Text] [PDF]


Home page
JRSMHome page
M. Koller and W. Lorenz
Quality of life: a deconstruction for clinicians
J R Soc Med, January 10, 2002; 95(10): 481 - 488.
[Full Text] [PDF]


Home page
StrokeHome page
P. N. Post, A. M. Stiggelbout, and P. P. Wakker
The Utility of Health States After Stroke : A Systematic Review of the Literature
Stroke, June 1, 2001; 32(6): 1425 - 1429.
[Abstract] [Full Text] [PDF]



About
JCO
 Editorial
Roster
 Advertising
Information
 Librarians &
Institutions
 Rights &
Permissions
 PDA Services

Copyright © 2001 by the American Society of Clinical Oncology, Online ISSN: 1527-7755. Print ISSN: 0732-183X
Terms and Conditions of Use
  HighWire Press HighWire Press™ assists in the publication of JCO Online